Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Axios on your phone

Get breaking news and scoops on the go with the Axios app.

Download for free.

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Aïda Amer/Axios

For the first time, scientists have used the gene-editing technique CRISPR inside the body of an adult patient, in an effort to cure congenital blindness.

Why it matters: CRISPR has already been used to edit cells outside a human body, which are then reinfused into the patient. But the new study could open the door to using gene editing to treat incurable conditions that involve cells that can't be removed from the body, like Huntington's disease and dementia.

Details: The research was sponsored by the biotech companies Editas Medicine of Cambridge, Massachusetts and Allergan of Dublin, and was carried out at Oregon Health and Science University.

  • Scientists led by Eric Pierce of Harvard Medical School injected microscopic droplets carrying a benign virus into the eye of a nearly blind patient suffering from the genetic disorder Leber congenital amaurosis.
  • The virus had been engineered to instruct the cells to create CRISPR machinery. The hope is that CRISPR will edit out the genetic defects that cause blindness, restoring at least some vision.
  • "We literally have the potential to take people who are essentially blind and make them see," Charles Albright, chief scientific officer at Editas, told the AP.

Doctors had tried using in-the-body editing with a different tool called zinc fingers in 2017. But CRISPR is easier to employ and more effective at making precise gene edits.

  • "It gives us hope that we could extend that to lots of other diseases — if it works and if it's safe," National Institutes of Health director Francis Collins told NPR.

Go deeper: Genetic technology's double-edged sword

Go deeper

DOJ seizes 36 U.S. website domains for Iranian government disinformation

Iran's President-Elect Ebrahim Raisi holds a press conference at Shahid Beheshti conference hall in Tehran on Monday. Photo: Majid Saeedi/Getty Images

American officials seized 36 news website domains linked to Iran's government for spreading disinformation as part of a propaganda campaign, the Department of Justice said Tuesday.

Why it matters: The action comes at a time of heightened tension between the two countries, with Iran's hardline President-elect Ebrahim Raisi on Monday ruling out negotiating over missiles or meeting with President Biden as the two nations hold talks on returning Tehran to the 2015 nuclear deal.

NYT: Khashoggi's killers had paramilitary training in U.S.

A vigil for journalist Jamal Khashoggi outside the Saudi Arabia consulate in Istanbul, following his killing in 2018 in Turkey. Photo: Chris McGrath/Getty Images

Several Saudis who took part in the killing of Washington Post journalist Jamal Khashoggi had paramilitary training in the U.S. under a State Department contract a year before his 2018 death, the New York Times reported Tuesday.

Why it matters: While there's no evidence the department knew that Crown Prince Mohammed bin Salman sanctioned Saudi officials to detain, kidnap and torture dissidents in 2017, the approval of such training underscores how "intensely intertwined" the U.S. has become with a nation known for human rights abuses, per the NYT.

U.S. attorney finalist trashes Labor secretary

Rachael Rollins and Marty Walsh. Photos: Jessica Rinaldi/The Boston Globe via Getty Images (Rollins); Tom Williams/CQ-Roll Call Inc. via Getty Images (Walsh)

A finalist for U.S. attorney in Boston is publicly trashing the city's former mayor — Labor Secretary Marty Walsh.

Why it matters: Rachael Rollins’ approach is perpetuating scrutiny of a troubled Cabinet secretary and fellow Democrat — and hints at the independence she may exhibit if tapped for top federal prosecutor for the eastern half of Massachusetts.